Antibiotics in acute exacerbations of chronic bronchitis (Q37727171)

22 August 2017

1 reference

title

Antibiotics in acute exacerbations of chronic bronchitis (English)

1 reference

22 August 2017

0 references

Sanjay Sethi

1

1 reference

22 August 2017

1 April 2010

1 reference

Expert Review of Anti-infective Therapy

22 August 2017

1 reference

22 August 2017

8

1 reference

22 August 2017

4

1 reference

22 August 2017

405-417

1 reference

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

22 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Costs of chronic bronchitis and COPD: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Exacerbations of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Toward a consensus definition for COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Infection in the pathogenesis and course of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Pseudomonas aeruginosa in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Haemophilus haemolyticus: a human respiratory tract commensal to be distinguished from Haemophilus influenzae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Chlamydia pneumoniae infection in patients with diffuse panbronchiolitis and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Tigecycline: an expanded broad-spectrum intravenous antibiotic. Preface and summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae: worldwide results from PROTEKT 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Hospital admissions for pneumonia in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Pulmonary disposition of antimicrobial agents: methodological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

The problems of meta-analysis for antibiotic treatment of chronic obstructive pulmonary disease, a heterogeneous disease: a commentary on Puhan et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

The Role of Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Effect of Various Antimicrobial Regimens on the Clinical Course of Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease in Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERI.09.133

Antibiotics for exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD004403.PUB2

Identifiers

DOI

10.1586/ERI.09.133

1 reference

22 August 2017

1 reference

PubMed ID

20377336